Literature DB >> 16129510

Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.

Avinash Viswanathan, Giancarlo Pillot, Ramaswamy Govindan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16129510     DOI： 10.1016/j.lungcan.2005.07.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  12 in total

1.  Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Authors:  Daniel B Costa; Kim-Son H Nguyen; Byoung C Cho; Lecia V Sequist; David M Jackman; Gregory J Riely; Beow Y Yeap; Balázs Halmos; Joo H Kim; Pasi A Jänne; Mark S Huberman; William Pao; Daniel G Tenen; Susumu Kobayashi
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

2.  T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

Authors:  Chunyan Ma; Shuzhen Wei; Yong Song
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

Review 3.  Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.

Authors:  Navneet Singh; Aditya Jindal; Digambar Behera
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

Authors:  Jae Cheol Lee; Seung Hun Jang; Kye Young Lee; Young-Chul Kim
Journal:  Cancer Res Treat       Date:  2013-06-30       Impact factor: 4.679

5.  Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.

Authors:  D H Lee; S-W Kim; C Suh; D H Yoon; E J Yi; J-S Lee
Journal:  Ann Oncol       Date:  2008-07-21       Impact factor: 32.976

6.  Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.

Authors:  Hoon-Kyo Kim; Myeong Im Ahn; Jinyoung Yoo; Chi Hong Kim; Hong-Jun Yang; Byoung Yong Shim
Journal:  Cancer Res Treat       Date:  2007-03-31       Impact factor: 4.679

7.  Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Authors:  Satoshi Watanabe; Junta Tanaka; Takeshi Ota; Rie Kondo; Hiroshi Tanaka; Hiroshi Kagamu; Kosuke Ichikawa; Jun Koshio; Junko Baba; Takao Miyabayashi; Ichiei Narita; Hirohisa Yoshizawa
Journal:  BMC Cancer       Date:  2011-01-01       Impact factor: 4.430

8.  Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.

Authors:  Matthew K Wong; Alvis I Lo; Bing Lam; W K Lam; Mary S Ip; James C Ho
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-13       Impact factor: 3.333

9.  Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor.

Authors:  Chih-Jen Yang; Ming-Ju Tsai; Jen-Yu Hung; Ying-Ming Tsai; Jui-Ying Lee; Shah-Hwa Chou; Ta-Chih Liu; Mei-Chiou Shen; Ming-Shyan Huang; Inn-Wen Chong
Journal:  Onco Targets Ther       Date:  2016-03-15       Impact factor: 4.147

10.  Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.

Authors:  Kyoung Min Cho; Bhumsuk Keam; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.